ATE397218T1 - Epf-rezeptorassays, verbindungen und therapeutische zusammensetzungen - Google Patents
Epf-rezeptorassays, verbindungen und therapeutische zusammensetzungenInfo
- Publication number
- ATE397218T1 ATE397218T1 AT02745422T AT02745422T ATE397218T1 AT E397218 T1 ATE397218 T1 AT E397218T1 AT 02745422 T AT02745422 T AT 02745422T AT 02745422 T AT02745422 T AT 02745422T AT E397218 T1 ATE397218 T1 AT E397218T1
- Authority
- AT
- Austria
- Prior art keywords
- epf
- assays
- compounds
- test compound
- therapeutic compositions
- Prior art date
Links
- 238000003556 assay Methods 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000003993 interaction Effects 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 abstract 1
- 230000002860 competitive effect Effects 0.000 abstract 1
- 239000013642 negative control Substances 0.000 abstract 1
- 230000036963 noncompetitive effect Effects 0.000 abstract 1
- 239000013641 positive control Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Pathology (AREA)
- Reproductive Health (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pregnancy & Childbirth (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01202474 | 2001-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE397218T1 true ATE397218T1 (de) | 2008-06-15 |
Family
ID=8180549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02745422T ATE397218T1 (de) | 2001-06-27 | 2002-06-26 | Epf-rezeptorassays, verbindungen und therapeutische zusammensetzungen |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20040235722A1 (de) |
| EP (1) | EP1399744B1 (de) |
| JP (1) | JP4326326B2 (de) |
| KR (2) | KR100971270B1 (de) |
| CN (1) | CN100406891C (de) |
| AT (1) | ATE397218T1 (de) |
| AU (1) | AU2002317013B2 (de) |
| CA (1) | CA2450502C (de) |
| DE (1) | DE60226867D1 (de) |
| DK (1) | DK1399744T3 (de) |
| ES (1) | ES2307767T3 (de) |
| IL (2) | IL158817A0 (de) |
| NO (1) | NO341778B1 (de) |
| NZ (1) | NZ529714A (de) |
| WO (1) | WO2003005036A2 (de) |
| ZA (1) | ZA200309823B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1340979A3 (de) * | 2002-02-27 | 2004-02-04 | Pfizer Limited | Neuropeptid Rezeptor und dessen Anwendungen |
| JP4991291B2 (ja) * | 2003-06-20 | 2012-08-01 | ディスカバーエクス コーポレイション | タンパク質結合を検出するための検定法およびキット |
| CN101309934B (zh) | 2005-08-31 | 2014-02-12 | 悉生物有限公司 | 修饰的伴侣蛋白10 |
| CN101514335B (zh) * | 2008-02-22 | 2013-04-17 | 中国科学院生物物理研究所 | 流感病毒聚合酶亚基pa的表达纯化及pa氨基端及pa羧基端与pb1氨基端多肽复合体的晶体结构 |
| CA2720617A1 (en) * | 2008-04-11 | 2009-10-15 | Cbio Limited | Modified cpn10 and prr signalling |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT731811E (pt) * | 1993-11-30 | 2005-04-29 | Univ Queensland | Chaperonina 10 |
| US5989804A (en) * | 1994-07-08 | 1999-11-23 | New England Medical Center Hospitals, Inc. | E6 binding proteins |
| SE9704836D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Pharma Inc | Novel receptor |
| EP1053473A4 (de) * | 1998-02-02 | 2003-08-13 | Concepto Diagnostics Inc | Verfahren und vorrichtung zum nachweis der empfängnis bei tieren |
| CN1379816A (zh) * | 1999-09-16 | 2002-11-13 | 索尔瓦药物有限公司 | 人g-蛋白偶联受体 |
| CA2390547A1 (en) * | 1999-11-17 | 2001-05-25 | Arena Pharmaceuticals, Inc. | Endogenous and non-endogenous versions of human g protein-coupled receptors |
-
2002
- 2002-06-26 CN CN028131754A patent/CN100406891C/zh not_active Expired - Fee Related
- 2002-06-26 EP EP02745422A patent/EP1399744B1/de not_active Expired - Lifetime
- 2002-06-26 US US10/481,161 patent/US20040235722A1/en not_active Abandoned
- 2002-06-26 DE DE60226867T patent/DE60226867D1/de not_active Expired - Lifetime
- 2002-06-26 KR KR1020097019090A patent/KR100971270B1/ko not_active Expired - Fee Related
- 2002-06-26 WO PCT/EP2002/007263 patent/WO2003005036A2/en not_active Ceased
- 2002-06-26 DK DK02745422T patent/DK1399744T3/da active
- 2002-06-26 JP JP2003510961A patent/JP4326326B2/ja not_active Expired - Fee Related
- 2002-06-26 AU AU2002317013A patent/AU2002317013B2/en not_active Ceased
- 2002-06-26 ES ES02745422T patent/ES2307767T3/es not_active Expired - Lifetime
- 2002-06-26 IL IL15881702A patent/IL158817A0/xx unknown
- 2002-06-26 CA CA2450502A patent/CA2450502C/en not_active Expired - Fee Related
- 2002-06-26 AT AT02745422T patent/ATE397218T1/de active
- 2002-06-26 NZ NZ529714A patent/NZ529714A/en not_active IP Right Cessation
- 2002-06-26 KR KR1020037014859A patent/KR100977824B1/ko not_active Expired - Fee Related
-
2003
- 2003-11-11 IL IL158817A patent/IL158817A/en not_active IP Right Cessation
- 2003-12-18 ZA ZA2003/09823A patent/ZA200309823B/en unknown
- 2003-12-22 NO NO20035771A patent/NO341778B1/no not_active IP Right Cessation
-
2006
- 2006-03-22 US US11/387,009 patent/US7402563B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| NZ529714A (en) | 2008-04-30 |
| IL158817A0 (en) | 2004-05-12 |
| US7402563B2 (en) | 2008-07-22 |
| JP4326326B2 (ja) | 2009-09-02 |
| US20040235722A1 (en) | 2004-11-25 |
| EP1399744A2 (de) | 2004-03-24 |
| JP2005503543A (ja) | 2005-02-03 |
| KR20090111346A (ko) | 2009-10-26 |
| CA2450502A1 (en) | 2003-01-16 |
| KR100977824B1 (ko) | 2010-08-25 |
| AU2002317013B2 (en) | 2007-11-01 |
| NO20035771L (no) | 2004-02-26 |
| WO2003005036A3 (en) | 2003-10-16 |
| CN100406891C (zh) | 2008-07-30 |
| KR20040010644A (ko) | 2004-01-31 |
| ZA200309823B (en) | 2005-05-25 |
| IL158817A (en) | 2012-01-31 |
| WO2003005036A2 (en) | 2003-01-16 |
| HK1070694A1 (zh) | 2005-06-24 |
| US20060160145A1 (en) | 2006-07-20 |
| CN1541335A (zh) | 2004-10-27 |
| EP1399744B1 (de) | 2008-05-28 |
| NO341778B1 (no) | 2018-01-15 |
| DE60226867D1 (de) | 2008-07-10 |
| DK1399744T3 (da) | 2008-09-22 |
| ES2307767T3 (es) | 2008-12-01 |
| KR100971270B1 (ko) | 2010-07-20 |
| CA2450502C (en) | 2017-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Auger et al. | Influence of HLA–DR genes on the production of rheumatoid arthritis–specific autoantibodies to citrullinated fibrinogen | |
| Nogueira et al. | Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis | |
| Yuan et al. | Highly sensitive time-resolved fluoroimmunoassay of human immunoglobulin E by using a new europium fluorescent chelate as a label | |
| BR0306150A (pt) | Composto, uso de um composto, e, composição farmacêutica | |
| ATE343591T1 (de) | Antagonist für die multimerisierung von hiv-1 vif-protein | |
| BR0110079A (pt) | Combinação de compostos orgânicos | |
| ATE478336T1 (de) | Immunologische assays und antikörper für das anti-müller-hormon | |
| IL209481A0 (en) | Preimplantation factor peptide | |
| BR0113213A (pt) | Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo | |
| FI961004A0 (fi) | Määrityspakkaus | |
| Wu et al. | Functional proteomics approaches for the identification of transnitrosylase and denitrosylase targets | |
| ATE397218T1 (de) | Epf-rezeptorassays, verbindungen und therapeutische zusammensetzungen | |
| DK2005190T4 (da) | Inhibering af GASC1 | |
| Maqueda et al. | The heparin III-binding domain of fibronectin (III4–5 repeats) binds to fibronectin and inhibits fibronectin matrix assembly | |
| CN101936985B (zh) | 一种检测己烯雌酚的方法及其专用化学发光免疫试剂盒 | |
| DK1214447T3 (da) | Påvisning af pyruvatkinase-isoenzymer i fæces | |
| CN113804873B (zh) | 确定体内受体占有率的测定 | |
| WO2005103713A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| ATE502300T1 (de) | Immunoassay-verfahren | |
| BR0308890A (pt) | Composto | |
| Lim et al. | Early-stage HIV infection and hepatitis C virus infection are associated with elevated serum porphyrin levels | |
| EP1991871A4 (de) | Neues testverfahren zum nachweis eines an einen zellmembranrezeptor gebundenen antikörpers | |
| ATE478039T1 (de) | Assays für amphetamin und methamphetamin | |
| Lee et al. | Development of ELISA system for screening of specific binding inhibitors for Src homology (SH) 2 domain and phosphotyrosine interactions | |
| ATE408144T1 (de) | Assays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1399744 Country of ref document: EP |